Publications by authors named "M Schipper"
Prostate-specific membrane antigen (PSMA) PET was approved by the U.S. Food and Drug Administration in 2020 for the staging of newly diagnosed prostate cancer, yet rates of adoption and real-world positivity rates are unknown.
View Article and Find Full Text PDFRecent advancements in Parkinson's disease (PD) drug development have been significantly driven by genetic research. Importantly, drugs supported by genetic evidence are more likely to be approved. While genome-wide association studies (GWAS) are a powerful tool to nominate genomic regions associated with certain traits or diseases, pinpointing the causal biologically relevant gene is often challenging.
View Article and Find Full Text PDFPurpose: Prospective trials have reported isotoxicity and improved oncologic outcomes with external beam radiation therapy (EBRT) microboost to a dominant intraprostatic lesion. There is often variability in the rate of adoption of new treatments, and current microboost practice patterns are unknown. We leveraged prospectively collected data from the multicenter Michigan Radiation Oncology Quality Consortium to understand the current state of microboost usage for localized prostate cancer.
View Article and Find Full Text PDFBackground: Black patients were severely under-represented in the clinical trials that led to the approval of immune checkpoint inhibitors (ICIs) for all cancers. The aim of this study was to characterise the effectiveness and safety of ICIs in Black patients.
Methods: We did a retrospective cohort study of patients in the US Veterans Health Administration (VHA) system's Corporate Data Warehouse containing electronic medical records for all patients who self-identified as non-Hispanic Black or African American (referred to as Black) or non-Hispanic White (referred to as White) and received PD-1, PD-L1, CTLA-4, or LAG-3 inhibitors between Jan 1, 2010, and Dec 31, 2023.
Article Synopsis
- This study examined the prevalence of post-acute sequelae of COVID-19 (PASC) symptoms in individuals infected with Delta and Omicron variants, comparing them to a control group over a 12-month period.
- Participants completed surveys every three months about their symptoms and severity levels for various PASC-associated symptoms, revealing a higher prevalence initially for Delta cases compared to Omicron.
- PASC prevalence dropped from 34.3% to 21.7% for Delta and from 18.7% to 16.7% for Omicron over the study period, with no significant difference between the two by the end of the 12 months.